Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004927 · ClinicalTrials.gov registry record · Phase 1
BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
A Phase 1 study, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004927 is a Phase 1 study that has completed, run by R-Pharm.
The verdict
NCT00004927, a Phase 1 study, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors that have not responded to previous therapy.
Interventions
- DRUG ixabepilone
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Est. Completion | 2002-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004927
The ClinicalTrials.gov registry entry for NCT00004927 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ixabepilone is the first listed.
NCT00004927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004927 about?
NCT00004927 is a clinical study titled "BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors that have not responded to previous therapy.
What is the current status of trial NCT00004927?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-07. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00004927?
The interventions under investigation include: ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00004927?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.